Small Cell Lung Cancer Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer (Camel-01)
Conditions: SCLC, Limited Stage Interventions: Drug: Durvalumab; Drug: Chemotherapy drug of EP regimen; Radiation: radiotherapy Sponsors: Hebei Medical University Fourth Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 17, 2024 Category: Research Source Type: clinical trials

Efficacy and Safety of DEB-BACE Combined With Serplulimab in First-line Treatment of SCLC
Conditions: Carcinoma; Small Cell Lung Cancer Interventions: Procedure: Drug-eluting beads bronchial arterial chemoembolization; Drug: Serplulimab; Procedure: Intravenous chemotherapy Sponsors: The Central Hospital of Lishui City Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials

Testing the Addition of Radiation Therapy to the Immune Therapy Treatment for ES-SCLC
Conditions: Extensive Stage Lung Small Cell Cancer Interventions: Drug: Serplulimab; Radiation: Chest Radiation Sponsors: Zhejiang Cancer Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 5, 2024 Category: Research Source Type: clinical trials

Phase I Clinical Study of α-PD-L1/DLL3 CAR-T in Patients With R/R SCLC
Conditions: Small Cell Lung Cancer Extensive Stage Interventions: Drug: α-PD-L1/4-1BB DLL3 CAR-T (BHP01) Sponsors: Sichuan University; Chengdu Brilliant Pharmaceutical Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 5, 2024 Category: Research Source Type: clinical trials

Safety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-treated With Immunotherapy
Conditions: Extensive-stage Small-cell Lung Cancer Interventions: Drug: Adebrelimab, Irinotecan Liposome (II); Drug: Adebrelimab, Irinotecan Liposome (II), Famitinib Sponsors: Baohui Han Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 27, 2024 Category: Research Source Type: clinical trials

A Study of Adebrelimab Combined With Famitinib and Chemotherapy in the Treatment of ES-SCLC.
Conditions: Extensive-stage Small-cell Lung Cancer Interventions: Drug: adebrelimab; Drug: famitinib; Drug: chemotherapy Sponsors: Harbin Medical University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 12, 2024 Category: Research Source Type: clinical trials

Serplulimab Combined With CCRT for LS-SCLC.
Conditions: Small Cell Lung Cancer Interventions: Drug: Serplulimab Sponsors: Peking Union Medical College Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 6, 2024 Category: Research Source Type: clinical trials

A Multicenter, Real-world Study of Adebrelimab in the Treatment of Extensive Stage Small Cell Lung Cancer
Conditions: SCLC,Extensive Stage Interventions: Drug: Adebrelimab Sponsors: Henan Cancer Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 20, 2024 Category: Research Source Type: clinical trials

Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC
Conditions: Small Cell Lung Cancer Recurrent Interventions: Drug: Irinotecan Liposome; Drug: Anlotinib Sponsors: Fudan University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 14, 2024 Category: Research Source Type: clinical trials

WBRT With Hippocampal-avoidance Technique Followed by SRT for Extensive-stage SCLC With Baseline Brain Metastases
Conditions: SCLC,Extensive Stage; Brain Metastases Interventions: Radiation: HA-WBRT plus SBRT Sponsors: Fudan University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 5, 2024 Category: Research Source Type: clinical trials

Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC
Conditions: Extensive-stage Small-cell Lung Cancer Interventions: Radiation: Thoracic Radiochemotherapy; Drug: durvalumab; Radiation: Stereotactic radiotherapy of further tumor locations; Drug: Chemotherapy Sponsors: Universit ät des Saarlandes Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 25, 2024 Category: Research Source Type: clinical trials

Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC
Conditions: Lung Cancer; Extensive-stage Small-cell Lung Cancer Interventions: Radiation: Low-dose radiotherapy; Drug: Etoposide; Drug: Cisplatin; Drug: Sugemalimab; Drug: Olaparib Sponsors: Sichuan University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 22, 2024 Category: Research Source Type: clinical trials

Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
Conditions: Extensive-Stage Small-Cell Lung Cancer; Small-Cell Lung Cancer Interventions: Drug: Tarlatamab; Drug: Durvalumab Sponsors: Amgen Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 18, 2024 Category: Research Source Type: clinical trials

Thoracic Consolidation Radiotherapy for ES-SCLC Treated With Chemo-immunotherapy
Conditions: Small Cell Lung Cancer Extensive Stage Interventions: Radiation: thoracic radiotherapy Sponsors: Fudan University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 3, 2024 Category: Research Source Type: clinical trials

An Open-label, Multicenter Study of ZL-1310 in Subjects With Small Cell Lung Cancer
Conditions: SCLC Interventions: Drug: ZL-1310 Sponsors: Zai Lab (Shanghai) Co., Ltd.; Zai Lab (US) LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 21, 2023 Category: Research Source Type: clinical trials